
Oscar Health (OSCR) Stock Forecast & Price Target
Oscar Health (OSCR) Analyst Ratings
Bulls say
Oscar Health Inc. demonstrated a significant year-over-year revenue increase of 29.0%, reaching $2.86 billion in the second quarter of 2025, attributed to strong customer retention and member additions. The company's medical loss ratio (MLR) improved to 91.1%, better than consensus expectations, indicating efficient management of healthcare costs despite increasing market morbidity. Additionally, projected enrollment weighted direct policy premiums per member per month (PMPM) are expected to rise by 28.5% in 2026 and 16.9% in 2027, reflecting robust growth potential in its insurance offerings.
Bears say
Oscar Health's stock outlook appears negative due to anticipated declines in enrollment in the Individual ACA Marketplace, with projections indicating a potential decrease of 20% to 30% in CY26, translating to a loss of approximately 6.1 million members year-over-year. The company's strategy to shift its insurance mix towards Bronze plans, while notable, may not offset the adverse impact of reduced enrollment and potential attrition among healthier members in a cost-cutting environment. Additionally, despite a slight improvement in SG&A ratios and an adjusted EBITDA margin of 2.4%, the overall financial health may remain under pressure if market conditions deteriorate further.
This aggregate rating is based on analysts' research of Oscar Health and is not a guaranteed prediction by Public.com or investment advice.
Oscar Health (OSCR) Analyst Forecast & Price Prediction
Start investing in Oscar Health (OSCR)
Order type
Buy in
Order amount
Est. shares
0 shares